Home > Company News > Rule 2.10 Announcement

Rule 2.10 Announcement

March 2nd 2010

Cyprotex PLC

(“Cyprotex” or the “Company”)

Rule 2.10 Announcement

Pursuant to Rule 2.10 of the City Code on Mergers and Acquisitions (the "Code"), Cyprotex confirms that it has 178,957,188 ordinary shares of 0.1p each ("Ordinary Shares"), in issue and admitted to trading on the AIM market of the London Stock Exchange. The International Securities Identification Number for the ordinary shares is GB0031214470.
Rule 19.11 disclosure

In accordance with Rule 19.11 of the Code, a copy of this Announcement will be published on the Cyprotex website: www.cyprotex.com.

Enquiries:

Cyprotex PLC
Anthony Baxter CEO
01625 505100
ir@cyprotex.com
www.cyprotex.com

Execution Noble & Company Limited
John Llewellyn-Lloyd / Sam Reynolds
020 7456 9191

Public Relations
Financial Dynamics
Ben Brewerton / Ben Atwell / John Dineen
020 7831 3113

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

Email:
enquiries@cyprotex.com

or fill out the form below:

First name (required) Last name (required) Email address (required) Job title (required) How did you hear about us?

Town / City County / State Company (required) Contact phone number Country (required)

Your requirements

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Number of compounds

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Opt-in to Cyprotex news